

# Summary

<b>Preface</b> .....	1
<b>Introduction</b> .....	3
Healthcare Dilemma.....	3
Opportunity Cost.....	4
Efficiency and Equity .....	5
HTA and Pharmacoeconomics .....	7
Pharmacoeconomics .....	11
Sensitivity Analysis.....	13
Summary.....	14
Questions .....	15
Answers .....	16
References and Further Readings.....	17
<b>1 Principles of Epidemiology</b> .....	19
<b>1.1 Introduction</b> .....	19
<b>1.2 Study Design</b> .....	20
Non-Experimental Studies .....	20
Experimental Studies.....	24
Non-Randomized Studies .....	31
Systematic and Narrative Reviews .....	32
<b>1.3 Bias in Epidemiology</b> .....	33
Selection Bias .....	34
Information Bias.....	35
Confounding.....	36
<b>1.4 Measures of Occurrence</b> .....	37
Incidence.....	37
Prevalence.....	38
<b>1.5 Measures of Association</b> .....	39
Contingency Tables .....	39
Relative Risk .....	39
Risk Difference .....	41
Odds Ratio.....	42
Hazard Ratio.....	43

<b>1.6</b>	<b>Regressions: How to Interpret Results</b> .....	43
	Univariate Linear Regression Model .....	44
	Multivariate Linear Regression Model.....	46
	Questions.....	48
	Answers .....	49
	References.....	50
<b>2</b>	<b>Definitions and Basic Concepts</b> .....	53
<b>2.1</b>	<b>Definitions</b> .....	53
<b>2.2</b>	<b>Costs</b> .....	54
<b>2.3</b>	<b>Consequences</b> .....	56
	Economic Outcomes.....	56
	Patient Outcomes.....	56
<b>2.4</b>	<b>Perspectives</b> .....	58
<b>2.5</b>	<b>Time Horizon</b> .....	58
	Discounting.....	59
	Questions.....	61
	Answers .....	62
	References.....	63
<b>3</b>	<b>Pharmacoeconomic Evaluations</b> .....	65
<b>3.1</b>	<b>Introduction</b> .....	65
<b>3.2</b>	<b>Cost Analysis</b> .....	66
	Cost of Care.....	66
<b>3.3</b>	<b>Cost-Outcomes Analysis</b> .....	67
	Cost-Effectiveness.....	67
<b>3.4</b>	<b>Multicriteria Decision Analysis</b> .....	70
	Example: MCDA in Communicable e Non-Communicable Disease .....	71
	Cost-Utility.....	73
	Cost-Minimization.....	73
	Cost-Benefit .....	73
	Cost-Consequence Analysis .....	74
<b>3.5</b>	<b>Utility</b> .....	74
<b>3.6</b>	<b>Psychometrics</b> .....	75
	Questions.....	78
	Answers .....	81
	References.....	82

<b>4</b>	<b>Modeling Frameworks</b> .....	85
4.1	Introduction.....	86
4.2	Microsimulation or Cohort Modeling?.....	87
	Example: Microsimulation Model in HIV.....	88
4.3	Steps in Decision Analysis.....	89
	Example: How to Develop a Model for Emergency Contraception and Pregnancy?... 89	
	Problem Conceptualization.....	89
	Model Conceptualization.....	90
	Model Parameter Estimation.....	92
	Run the Model and Interpretation.....	93
	Sensitivity Analysis, Transparency, and Validation.....	95
4.4	Markov Models.....	96
	Example: Markov Model in the Treatment of Secondary Hyperparathyroidism.....	97
4.5	Partitioned Survival Models.....	100
	Example: PSM in Advanced or Unresectable Hepatocellular Carcinoma.....	100
4.6	Discrete-Event Simulation.....	103
	Example: DES Model in TPN.....	103
4.7	Discretely Integrated Condition Event Simulation.....	106
	Example: How to Develop a DICE Model in Cancer.....	107
4.8	Agent-Based Models.....	108
	Example: AB Model in Screening Program.....	109
4.9	Conclusions.....	110
	Questions.....	112
	Answers.....	114
	References.....	115
<b>5</b>	<b>Budget Impact Analysis</b> .....	119
5.1	Introduction.....	119
5.2	Example: Budget Impact Analysis of Apixaban to Treat and Prevent Venous Thromboembolism in Italy.....	122
	Questions.....	126
	Answers.....	126
	References.....	127
<b>6</b>	<b>Patient Reported Outcomes</b> .....	129
6.1	From Physiological Measures to Patient Reported Outcome.....	130

<b>6.2</b>	<b>Quality of Life, Health-Related Quality of Life, and Patient Reported Outcomes</b> .....	131
	Quality of Life.....	131
	Health-Related Quality of Life.....	132
	Patient Reported Outcomes.....	133
<b>6.3</b>	<b>Individual Health and Circumstantial Perceptions and Experiences</b> .....	134
<b>6.4</b>	<b>Applications of PRO Instruments</b> .....	136
<b>6.5</b>	<b>Identifying an Appropriate Instrument for Measuring PRO</b> .....	138
<b>6.6</b>	<b>When are the Results of PROs Relevant?</b> .....	141
<b>6.7</b>	<b>Summary and Conclusion</b> .....	142
	Questions.....	143
	Answers.....	144
	References.....	145
<b>7</b>	<b>Data Sources and Accounting for Uncertainty</b> .....	153
<b>7.1</b>	<b>Data Sources</b> .....	153
	Clinical Epidemiology.....	154
	Literature Analysis.....	155
	Clinical Studies.....	161
	Administrative Databases.....	161
	Financial Data.....	164
<b>7.2</b>	<b>Statistical Analysis</b> .....	164
<b>7.3</b>	<b>Accounting for Uncertainty</b> .....	166
	Definition of Error.....	166
	Principal Sources of Error in Clinical Studies.....	166
	Reducing Error in Clinical Studies.....	167
	Selection Bias in Subjects Entering the Study.....	167
	Selection Bias in Subjects After Entering the Study.....	170
<b>7.4</b>	<b>Pharmacoeconomic Studies</b> .....	170
	Sensitivity Analysis.....	170
<b>7.5</b>	<b>Conclusions: Evaluating Pharmacoeconomic Studies</b> .....	177
	Questions.....	178
	Answers.....	181
	References.....	182
	<b>Glossary</b> .....	187
	<b>Authors</b> .....	193